This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Description: IFX-3 is a bi-specific monoclonal antibody designed to simultaneously block an important factor of the complement pathway and another key inflammatory mediator.
Additional information available to subscribers only: